Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss ...

The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis ...

In a report released today, Harry Sephton from UBS maintained a Hold rating on Sandoz Group Ltd (SDZXF – Research Report), with a price target ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...

Sandoz (SDZNY) announced the launch of Pyzchiva in the U.S. The medicine is now commercially available to patients across the U.S. Discover ...

More than 60 years of work by local artist Dave Nixon is exhibited in the Mari Sandoz High Plains Heritage Center.

(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.

Emasan AG, a subsidiary of the Sandoz Family Foundation, has initiated a public offering of approximately 26.5 million shares ...